CY1125297T1 - Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια - Google Patents

Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια

Info

Publication number
CY1125297T1
CY1125297T1 CY20211100886T CY211100886T CY1125297T1 CY 1125297 T1 CY1125297 T1 CY 1125297T1 CY 20211100886 T CY20211100886 T CY 20211100886T CY 211100886 T CY211100886 T CY 211100886T CY 1125297 T1 CY1125297 T1 CY 1125297T1
Authority
CY
Cyprus
Prior art keywords
chemotherapy
treatment
inhibitors
peripheral neuropathy
induced peripheral
Prior art date
Application number
CY20211100886T
Other languages
Greek (el)
English (en)
Inventor
Laura Brandolini
Pier Adelchi Ruffini
Marcello Allegretti
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16151618.2A external-priority patent/EP3192504A1/en
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of CY1125297T1 publication Critical patent/CY1125297T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20211100886T 2016-01-15 2021-10-14 Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια CY1125297T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16151618.2A EP3192504A1 (en) 2016-01-15 2016-01-15 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP16190871 2016-09-27
PCT/EP2017/050637 WO2017121838A1 (en) 2016-01-15 2017-01-13 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

Publications (1)

Publication Number Publication Date
CY1125297T1 true CY1125297T1 (el) 2023-03-24

Family

ID=57906595

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100886T CY1125297T1 (el) 2016-01-15 2021-10-14 Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια

Country Status (23)

Country Link
US (2) US12268671B2 (OSRAM)
EP (1) EP3402474B1 (OSRAM)
JP (1) JP7049254B2 (OSRAM)
KR (1) KR102737378B1 (OSRAM)
CN (1) CN108463219B (OSRAM)
AU (1) AU2017207850B2 (OSRAM)
CA (1) CA3009438A1 (OSRAM)
CY (1) CY1125297T1 (OSRAM)
DK (1) DK3402474T3 (OSRAM)
ES (1) ES2893701T3 (OSRAM)
HR (1) HRP20211527T1 (OSRAM)
HU (1) HUE056606T2 (OSRAM)
IL (1) IL260373B (OSRAM)
LT (1) LT3402474T (OSRAM)
MA (1) MA43861A (OSRAM)
MX (1) MX388815B (OSRAM)
PL (1) PL3402474T3 (OSRAM)
RS (1) RS62427B1 (OSRAM)
SG (1) SG11201804484YA (OSRAM)
SI (1) SI3402474T1 (OSRAM)
SM (1) SMT202100571T1 (OSRAM)
WO (1) WO2017121838A1 (OSRAM)
ZA (1) ZA201803486B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101914358B1 (ko) * 2017-01-18 2018-11-02 현대로템 주식회사 실내등 제어회로 및 이를 포함하는 철도차량
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
CN111343973A (zh) * 2017-10-24 2020-06-26 多姆皮制药公司 用于治疗一些肉瘤的il-8抑制剂
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
US20240115527A1 (en) * 2020-11-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4397305A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ATE444286T1 (de) 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
CA2664359A1 (en) 2006-09-26 2008-04-03 Case Western Reserve University Cytokine signaling
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
CR20160557A (es) * 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
RU2017106172A (ru) * 2014-07-31 2018-08-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)

Also Published As

Publication number Publication date
SI3402474T1 (sl) 2021-12-31
MA43861A (fr) 2021-05-05
ZA201803486B (en) 2019-09-25
US20190015391A1 (en) 2019-01-17
MX388815B (es) 2025-03-20
US12268671B2 (en) 2025-04-08
EP3402474A1 (en) 2018-11-21
CN108463219B (zh) 2021-09-17
DK3402474T3 (da) 2021-10-11
CA3009438A1 (en) 2017-07-20
MX2018008614A (es) 2018-11-19
CN108463219A (zh) 2018-08-28
HUE056606T2 (hu) 2022-02-28
JP2019501948A (ja) 2019-01-24
WO2017121838A1 (en) 2017-07-20
KR102737378B1 (ko) 2024-12-04
AU2017207850A1 (en) 2018-06-21
PL3402474T3 (pl) 2021-12-27
AU2017207850B2 (en) 2022-06-30
US20250195479A1 (en) 2025-06-19
HRP20211527T1 (hr) 2021-12-24
RS62427B1 (sr) 2021-11-30
NZ743344A (en) 2024-05-31
JP7049254B2 (ja) 2022-04-06
ES2893701T3 (es) 2022-02-09
SMT202100571T1 (it) 2021-11-12
SG11201804484YA (en) 2018-07-30
LT3402474T (lt) 2021-11-25
KR20180101390A (ko) 2018-09-12
IL260373B (en) 2021-03-25
EP3402474B1 (en) 2021-07-21
BR112018013570A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
CY1125297T1 (el) Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια
CY1126132T1 (el) Πυριδαζινονες ως αναστολεις parp7
CY1125245T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
EA202091540A1 (ru) Антитела к lilrb2
CY1125376T1 (el) Psma προσδετες για απεικονιση και ενδοακτινοθεραπεια
CY1121360T1 (el) Αναστολεις dna-pk
EA202092435A2 (ru) Моноклональные антитела против bcma
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
LT3986897T (lt) Egfr inhibitorius, skirtas vėžiui gydyti
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CU24498B1 (es) Anticuerpos de factor xi
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201691541A1 (ru) Новые анти-baff антитела
CY1120459T1 (el) Αντισωματα των χημειοκινων παν-elr+ cxc
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
CY1124413T1 (el) Ανταγωνιστες του υποδοχεα cgrp